Videos
Press Releases
22 Sep 2022
EORTC Quality of Life Group celebrating 40 years
31 Aug 2022
EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds
27 Jun 2022
PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation
17 Mar 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
Latest Newsletters
News
30 Jun 2023
“Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference
16 Jun 2023
Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma
9 Jun 2023
Joint Statement: health organisations define EHDS’ opt out required for life saving research
7 Jun 2023
Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award
6 Jun 2023
Full validation of the EORTC CAT Core
30 May 2023
Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types
25 May 2023
Publication of 2022 EORTC Annual Report
19 May 2023
EORTC is supporting Clinical Trials Day on 20th May
10 May 2023
Studying long-term survivors of glioblastoma may pave the way to better treatment
24 Apr 2023
Three new EORTC clinical trials funded by the EU
